PRS

Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024

Retrieved on: 
Tuesday, April 9, 2024
HER2, CD8, Phosphorylation, Survival, Cholangiocarcinoma, Immunotherapy, RECIST, Oncology, MAST, Patient, City, Degranulation, ASX, ADCC, Cancer, Hope, Overalls, Pembrolizumab, PRS, AACR, SPECT, Vaccination, Melanoma, Recurrence, PD-L1, IMU, Medical imaging

Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.

Key Points: 
  • Oncolytic virus CF33-hNIS (VAXINIA) alone or in combination with KEYTRUDA is a safe treatment option for advanced cancer patients.
  • SYDNEY, Australia, April 09, 2024 (GLOBE NEWSWIRE) -- Imugene Limited (ASX: IMU), a clinical stage immuno-oncology company, is pleased to announce poster presentations featuring its CF33 oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx at the American Association for Cancer Research (AACR) Annual Meeting 5-10 April 2024, in San Diego, CA.
  • HER-Vaxx induced HER2-specific antibodies able to mediate antibody-dependent cell cytotoxicity (ADCC) and inhibit intracellular HER2 phosphorylation and correlated with tumour reduction.
  • The HER-Vaxx induced HER2-specific antibodies demonstrate a similar mechanism of action to HERCEPTINâ validating B cell immunotherapy as an alternative anti-cancer agent to monoclonal antibodies.

Molecular Templates Presents Interim Data from MT-6402 Phase I Study in Patients with PD-L1+ Solid Tumors at the 2024 American Association for Cancer Research (AACR) Annual Meeting; Monotherapy Activity in Checkpoint-Experienced Head and Neck Cancer Patie

Retrieved on: 
Tuesday, April 9, 2024
Head, HNSCC, Patient, Tumor microenvironment, Cancer, PRS, Neoplasm, PD-L1, Cytokine, Poster, Therapy, ETB, VEGF, Pharmaceutical industry

The poster highlighted the following findings from the phase I dose-escalation study of MT-6402:

Key Points: 
  • The poster highlighted the following findings from the phase I dose-escalation study of MT-6402:
    MT-6402 acts uniquely from other approved checkpoint agents.
  • MT-6402 depletes immunosuppressive PD-L1+ immune cells and tumor cells, activates a T-effector phenotype, and remodels the tumor microenvironment to restore T-cell surveillance of the tumor.
  • An early monotherapy efficacy signal in head and neck squamous cell carcinoma (HNSCC) was identified.
  • The patients remain on study at cycles 19 and 10, respectively (one cycle = 4 weeks), demonstrating the potential for durable monotherapy activity with MT-6402.

Syncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024

Retrieved on: 
Monday, April 8, 2024
Failure, Toxicity, Disease, Patient, Nebraska Medicine, University, Cancer research, PRS, Freezing, AACR, Neoplasm, Metastasis, Immune system, ASCO, Medical research, CRS, Pharmaceutical industry

FORT LAUDERDALE, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, an in situ personalized therapy optimized for solid tumor cancers, today announced the presentation of positive results from the SV-102 Phase 1 trial at the American Association for Cancer Research (AACR) Annual Meeting 2024. The trial, involving patients with metastatic castrate-resistant prostate cancer (mCRPC), showed an overall response rate (ORR) of 85%.        

Key Points: 
  • FORT LAUDERDALE, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, an in situ personalized therapy optimized for solid tumor cancers, today announced the presentation of positive results from the SV-102 Phase 1 trial at the American Association for Cancer Research (AACR) Annual Meeting 2024.
  • The trial, involving patients with metastatic castrate-resistant prostate cancer (mCRPC), showed an overall response rate (ORR) of 85%.
  • The Phase 1 trial enrolled 15 mCRPC subjects, most of whom had diffuse bone metastases and had experienced failure with prior therapies.
  • The trial is ongoing, with results expected in the second half of 2024.

Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Friday, March 29, 2024
Head, Immunotherapy, HNSCC, Patient, Roche, Lead, Immunoglobulin G, Neoplasm, CRC, Audit committee, PD-1, Observation, Bioinformatics, Colorectal cancer, SAN, Information technology, Pembrolizumab, PRS, Safety, PD-L1, Compensated emancipation, Annual report, Apoptosis, Cervical cancer, Part, Merck, Senior, Bevacizumab, MSS, GAAP, ASCO, PFS, MTD, Liver disease, HCC, Therapeutic index, Endometrial cancer, Progression-free survival, ADS, Net, Regulatory T cell, Research and development, Liver, Pharmaceutical industry

SAN DIEGO and SUZHOU, China, March 29, 2024 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today reported financial results for the full year 2023 and provided corporate updates.

Key Points: 
  • Both confirmed PRs are sustained after more than one year with repeat dosing while maintaining robust safety profiles.
  • Observation of these clinical activities triggered further expansion into the second stage of the Simon’s 2-stage design for this dose level.
  • Net loss attributable to Adagene Inc.’s shareholders was US$18.9 million for the year ended December 31, 2023, compared to US$80.0 million in 2022.
  • The company encourages investors and others to review its financial information in its entirety and not rely on a single financial measure.

GTG Global Collaborations and Innovation Update

Retrieved on: 
Tuesday, March 26, 2024
Breast cancer, Health, General practice, Professor, BRCA, Public, Public health, Disease, GTG, Risk, Patient, PRS, Research, ASX, Breast, Mammography, University, Royal Melbourne Hospital, Trial of the century, WHI, Risk assessment, Sonneborn–Berger score, Council, Biobank, Publication, Clinical trial, Cancer, CLIA, Medical research, Colorectal cancer, University of Melbourne, Government, UK Biobank, Pharmaceutical industry

MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation.

Key Points: 
  • MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation.
  • GTG is one of the co-co-principal investigators of this trial led by Professor Jon Emery.
  • GTG regards adding new expanded risk assessment tests to the company’s portfolio as a critical step in improving patient care.
  • Leveraging this approach GTG is expanding the portfolio with the following new tests:
    Leveraging the BRCA-modifier research projects GTG will develop a test that incorporates high penetrant pathogenic variant risk with PRS.

TELA Bio Achieves Record Fourth Quarter and Full Year 2023 Revenues and Reports Complete Financial Results

Retrieved on: 
Thursday, March 21, 2024
Growth, Partnership, Anatomy, Webcast, Travel, PRS, Matrix, Sale, Hernia, MiMedx, Event, FDA, Video game

“The recalibration of our sales force over 2023 has led to increased productivity and an improved mix of sales across our product portfolio.

Key Points: 
  • “The recalibration of our sales force over 2023 has led to increased productivity and an improved mix of sales across our product portfolio.
  • 2023 was a great year that sets TELA Bio up for even more achievement in 2024!”
    Revenue was $17.0 million in the fourth quarter of 2023, an increase of 46% compared to the same period in 2022.
  • Operating expenses were $23.9 million in the fourth quarter of 2023, compared to $17.6 million in the same period in 2022.
  • TELA Bio will host a conference call at 4:30 p.m. Eastern Time on Thursday, March 21, 2024 to discuss its fourth quarter and full year 2023 financial results.

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, March 21, 2024
Research, Administration, Trastuzumab, Congress, Patient, Roche, Cancer, Trial of the century, PRS, ESMO, Operation, Research and development, ISAC, PD-1, Pharmaceutical industry

REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) --  Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Key Points: 
  • –   Cash balance of $128.6 million as of December 31, 2023, anticipated to fund key milestones through late 2025
    REDWOOD CITY, Calif., March 21, 2024 (GLOBE NEWSWIRE) --  Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  • “We made substantial progress advancing our two proprietary clinical-stage development programs in 2023,” said Randall Schatzman, Ph.D., Chief Executive Officer.
  • “We have now administered BDC-1001, which we have renamed trastuzumab imbotolimod, to patients in all five of the Phase 2 cohorts.
  • BDC-3042 also continues to advance, and has now entered the fourth dose escalation cohort without a dose-limiting toxicity.

NextCure Provides Business Update and Reports Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 21, 2024
Research, Toxicity, Bone disease, Agreement, Osteogenesis imperfecta, DAR, AML, Risk, Patient, MMAE, Mouse, OI, Public expenditure, Plaque, Apolipoprotein E, PRS, IND, ARIA, GMP, Osteoporosis, CRC, Workforce, Use, ADC, Osteoarthritis, FDA, GLP, Pharmaceutical industry

We plan to present the data of the CRC patients at a scientific conference within the second quarter of 2024.

Key Points: 
  • We plan to present the data of the CRC patients at a scientific conference within the second quarter of 2024.
  • Selected our first antibody drug conjugate (ADC) candidate of a potential of three from our collaboration with LegoChem Biosciences, Inc. (LegoChem).
  • Under the terms of the Agreement, both parties equally share the costs of developing the molecules and profits on commercialized products.
  • Implemented a restructuring plan to reduce operating costs and better align our workforce with the needs of our business.

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Tuesday, March 19, 2024
Atopic dermatitis, Head, T helper cell, HNSCC, Patient, PTCL, Lung cancer, Ipilimumab, Asthma, CTCL, ALCL, Fungal infection, Pulmonary fibrosis, Lymphocyte, RCC, Clinical trial, CRS, Marketing, B-cell lymphoma, Research, PR, PTCL-NOS, Psoriasis, T-cell lymphoma, ASH, Webcast, Immunomodulation, Pembrolizumab, PRS, Exposition, Cancer, Nivolumab, Safety, Scleroderma, Food, NSCLC, Teva Pharmaceuticals, Modified, Lymphoma, Knowledge, Allergy, Immunodeficiency, Time management, Peripheral, Poster, FDA, ITK, Conference call, Kidney cancer, T helper 17 cell, Society, Preprint, BioRxiv, Autoimmunity, Physician, Total, Pharmaceutical industry

BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.
  • We have several exciting opportunities in immunology, including plans for a randomized, placebo controlled clinical trial of soquelitinib in atopic dermatitis.
  • Mr. Arcara previously served as senior vice president, head global marketing & portfolio and strategy for the innovative medicines and biosimilars business at Teva Pharmaceuticals.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the fourth quarter and full year 2023 financial results.

Thoughtworks Technology Radar’s 30th Edition Highlights Teams Leveraging AI Across Software Delivery Lifecycle

Retrieved on: 
Wednesday, April 3, 2024
Professional Services, Engineering, Technology, Manufacturing, Software, Consulting, Artificial Intelligence, Organization, PDF, Documentation, Continue, GitHub Copilot, AI, PRS, LLM, Architecture, Radar, Multimedia, Risk management

These tools do much more than code generation; they can help with other facets of the software development lifecycle including testing, documentation creation and even refactoring.

Key Points: 
  • These tools do much more than code generation; they can help with other facets of the software development lifecycle including testing, documentation creation and even refactoring.
  • However, Thoughtworks notes that this space is still maturing — engineering teams need to remain vigilant and pragmatic in how they use these emerging tools.
  • "GenAI tools have the capacity to help software engineering teams in many different ways — they're more than coding assistants," said Rachel Laycock , Chief Technology Officer, Thoughtworks.
  • Highlighted themes in Technology Radar volume 30 include:
    AI-assisted software development teams: AI-assisted tools like GitHub Copilot , CodiumAI , aider and Continue influence almost every aspect of the software development lifecycle.